WS
ONCY

Wedbush Securities’s Oncolytics Biotech ONCY Stock Holding History

Wedbush Securities’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-111,600
Closed -$189K – 947
2020
Q3 		$189K Sell
111,600
-35,005
-24% -$64.2K 0.02% 772
2020
Q2 		$276K Buy
146,605
+101,900
+228% +$192K 0.03% 639
2020
Q1 		$62K Buy
+44,705
New +$112K 0.01% 814

Other funds holding ONCY

Creative Planning
Creative Planning Overland Park, Kansas $147B AUM 18.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
CIBC World Market
CIBC World Market Toronto, Ontario, Canada $61.3B AUM 39.33% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $570B AUM 27.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Wedbush Securities's ONCY Position: Q4 2020 in Review

Wedbush Securities sold out of Oncolytics Biotech (ONCY) in Q4 2020, closing a stake of 111,600 shares — an estimated $189K sold.

Wedbush Securities first reported a position in ONCY in Q1 2020 and held it in 3 quarters. The position peaked at $276K in Q2 2020. 36 funds tracked by Wall St. Rank hold ONCY as of Q4 2020.

  • Wedbush Securities reported no remaining Oncolytics Biotech position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 111,600 Oncolytics Biotech shares in Q4 2020, an estimated $189K.
  • Wedbush Securities first reported a position in Oncolytics Biotech in Q1 2020 and held it in 3 quarters.
  • Wedbush Securities's Oncolytics Biotech position peaked at $276K in Q2 2020.
  • 36 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.